Welcome to our dedicated page for Macrogenics SEC filings (Ticker: MGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MacroGenics, Inc. (MGNX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. MacroGenics states that it is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer, and its filings offer additional detail on this business through formal reports.
Recent Forms 8‑K filed by MacroGenics include items on quarterly financial and operating results, as well as leadership changes. For example, the company has filed current reports describing results of operations and financial condition for specific quarters and announcing the appointment of a new President and Chief Executive Officer. Another Form 8‑K discloses the planned departure of the Senior Vice President, Clinical Development and Chief Medical Officer and notes interim oversight arrangements for clinical development.
Through this page, users can review MacroGenics’ current reports alongside other SEC documents such as annual and quarterly reports when available. These filings often reference press releases that discuss clinical programs like lorigerlimab, antibody-drug conjugate candidates MGC026, MGC028 and MGC030, and partnered programs including MGD024, ZYNYZ® and TZIELD®, as well as collaboration and royalty structures described by the company.
Stock Titan enhances access to these materials with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the main topics in MacroGenics’ disclosures. Investors researching MGNX can use this page to follow official information on financial performance, executive transitions, material agreements and other events that MacroGenics reports to regulators.
MacroGenics senior vice president Thomas Spitznagel reported multiple equity transactions in February 2026. On February 12, 2026, he received 25,000 restricted stock units and an employee stock option for 150,000 shares of common stock at an exercise price of $1.71 per share.
On February 15, 2026, he exercised 13,332 restricted stock units, converting them into the same number of common shares, and 5,520 shares were disposed of at $1.71 per share to cover taxes or exercise costs. After these transactions, he directly owned 38,543 common shares of MacroGenics.
MacroGenics Inc. President and CEO Eric Blasius Risser reported several equity compensation moves. On February 12, 2026, he received 100,000 restricted stock units and 595,000 employee stock options, each tied to future vesting and exercisability conditions described in the filing.
On February 15, 2026, he exercised 16,665 restricted stock units, receiving the same number of common shares, and then disposed of 6,433 shares at $1.71 per share to cover tax obligations. After these transactions he directly owned 77,169 common shares of MacroGenics.
MacroGenics director Scott Koenig reported an RSU conversion into common stock. On February 15, 2026, he exercised restricted stock units and acquired 21,165 shares of MacroGenics common stock at a stated price of $0 per share, increasing his directly held position to 867,240 shares.
The RSUs were part of a 127,000-unit grant awarded on February 15, 2023. According to the disclosure, 84,670 units had vested before his separation from the company, and 21,165 additional units vested on August 13, 2025 under his Separation Agreement, with each RSU representing one share of common stock.
Frazier Life Sciences-affiliated funds and individuals have filed an amended Schedule 13G reporting no beneficial ownership of MacroGenics, Inc. common stock as of December 31, 2025. Each reporting person lists 0 shares beneficially owned and a 0.0% stake in the company’s common stock.
The filing covers multiple Frazier Life Sciences partnerships and LLCs, as well as James N. Topper and Patrick J. Heron, all organized in Delaware or the United States. They certify that any securities referenced were not acquired or held to change or influence control of MacroGenics, but rather on a passive basis.
MacroGenics director Scott Koenig converted 15,831 restricted stock units into an equal number of MacroGenics common shares on February 8, 2026, at an exercise price of $0 per share. After this conversion, he directly owned 846,075 shares of common stock and 15,832 RSUs.
The RSUs come from a 95,000-unit grant on February 8, 2024. One-third vested after one year, and half of the remaining units vested under a Separation Agreement on August 13, 2025. The rest vest in two equal annual installments on the grant anniversary.
MacroGenics, Inc. senior vice president Thomas Spitznagel reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,001 and 8,999 shares of common stock, respectively, on a one-for-one basis. On each date, 2,485 and 3,186 shares were withheld at $1.81 per share to cover taxes. After these transactions, Spitznagel directly owned 30,731 shares of MacroGenics common stock.
MacroGenics VP, Controller & Treasurer Beth Ann Smith reported routine equity compensation activity involving restricted stock units (RSUs) and common stock. On February 7, 2026, 2,617 RSUs converted into 2,617 shares of common stock at an exercise price of $0, with 1,011 shares of common stock withheld at $1.81 per share, leaving 11,138 shares directly owned afterward. On February 8, 2026, a further 1,583 RSUs converted into 1,583 shares of common stock at $0, with 612 shares withheld at $1.81 per share, resulting in 12,109 common shares directly owned. RSUs convert into company stock on a one-for-one basis, and remaining RSU balances after these transactions were 5,233 and 1,584 units for the two respective grants.
MacroGenics (MGNX) President and CEO Eric Blasius Risser reported multiple equity award transactions in early February 2026. On February 7, 2026, 6,668 restricted stock units (RSUs) converted on a one-for-one basis into common stock, increasing his direct holdings to 62,657 shares before a 2,575-share disposition at $1.81 per share, leaving 60,082 shares.
On February 8, 2026, a further 11,166 RSUs converted into common stock, taking his direct common stock position to 71,248 shares before a 4,311-share disposition at $1.81 per share, resulting in 66,937 common shares directly owned. Following these transactions, he held 13,332 RSUs from a February 7, 2025 grant of 20,000 units and 11,166 RSUs from a February 8, 2024 grant of 33,500 units, each vesting in three equal annual installments.
MacroGenics, Inc. insider activity: Senior VP, General Counsel and Secretary Jeffrey Stuart Peters reported routine equity compensation events. On February 7 and 8, 2026, portions of previously granted restricted stock units vested and were converted into common stock on a one-for-one basis.
On those dates, a total of 6,001 and 8,999 common shares, respectively, were acquired upon RSU conversion at an exercise price of $0. In connection with these vestings, 2,317 and 3,474 shares of common stock were withheld at $1.81 per share to satisfy tax obligations, coded as transaction type “F.”
Following the reported transactions, Peters directly held 22,920 shares of MacroGenics common stock. He also continued to hold derivative positions in restricted stock units from earlier grants, which were originally 18,000 units granted on February 7, 2025 and 27,000 units granted on February 8, 2024, each vesting in three equal annual installments.
MacroGenics SVP and CFO James Karrels reported routine equity award activity. On February 7 and 8, 2026, restricted stock units converted into 6,334 and 9,999 shares of common stock, respectively, on a one-for-one basis. In connection with these vestings, 2,446 and 3,860 shares of common stock were withheld at $1.81 per share to cover tax obligations.
After these transactions, Karrels beneficially owned 196,828 shares of MacroGenics common stock, held directly and jointly with his wife, plus 12,666 and 9,999 remaining restricted stock units from prior grants that continue to vest over time.